Abstract
D1 dopamine receptor binding in mood disorders was studied by positron emission tomography (PET) using11C-SCH23390. Ten patients with bipolar mood disorders and 21 normal controls were studied in the drug-free state. The patients were in euthymic (N=6), depressed (N=3) and manic (N=1) states. Regional radioactivity in the brain was followed for 40 min by PET. A two-compartment model was used to obtain the binding potential (k3/k4) for the striatum and frontal cortex. The binding potentials for the frontal cortex for the patients were significantly lower than those for normal controls, whereas those for striatum were not significantly different. These findings suggest that D1 dopamine receptors in the frontal cortex may be in a different state in patients with bipolar mood disorders.
Similar content being viewed by others
References
Andersen PH, Braestrup C (1986) Evidence for different states of the dopamine D1 receptor: clozapine and fluperlapine may preferentially label an adenylate cyclase-coupled state of the D1 receptor. J Neurochem 47:1822–1831
Andersen PH, Grønvald FC (1986) Specific binding of3H-SCH23390 to dopamine D1 receptors in vivo. Life Sci 38:1507–1514
Andersen PH, Gingrich JA, Bates MD, Dearry A, Falardeau P, Senogles SE, Caron MG (1990) Dopamine receptor subtypes: beyond the D1/D2 classification. TIPS 11:231–236
Antelman SM, Caggiula AR (1977) Norepinephrine-dopamine interaction and behavior. Science 195:646–653
Baxter LR Jr, Phelps ME, Mazziotta JC, Schwartz JM, Gerner RH, Selin CE, Sumida RM (1985) Cerebral metabolic rate for glucose in mood disorders. Arch Gen Psychiatry 42:441–447
Bischoff S, Heinrich M, Sonntag JM, Krauss J (1986) The D-1 dopamine receptor antagonist SCH23390 also interacts potently with brain serotonin (5-HT2) receptors. Eur J Pharmacol 129:367–370
Brière R, Diop L, Gottberg E, Grondin L, Reader T (1987) Stereospecific binding of a new benzazepine, [3H]SCH23390, in cortex and neostriatum. Can J Physiol Pharmacol 65:1507–1511
Chugani DC, Ackermann RF, Phelps ME (1988) In vivo [3H]spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization. J Cereb Blood Flow Metab 8:291–303
Cortés R, Gueye B, Pazos A, Probst A, Palacios JM (1989) Dopamine receptors in human brain: autoradiographic distribution of D1 sites. Neuroscience 28:263–273
Dawson TM, Mccabe RT, Stensaas SS, Wamsley JK (1987) Autoradiographic evidence of [3H]SCH23390 binding sites in human prefrontal cortex (Brodmann's area 9). J Neurochem 49:789–796
De Keyser J, Claeys A, De Backer JP, Ebinger G, Roels F, Vauquelin G (1988) Autoradiographic localization of D1 and D2 dopamine receptors in the human brain. Neurosci Lett 91:142–147
De Montis GM, Devoto P, Gessa GL, Meloni D, Porcella A, Saba P, Serra G, Tagliamonte A (1989) Chronic imipramine reduces [3H]SCH23390 binding and DA-sensitive adenylate cyclase in the limbic system. Eur J Pharmacol 167:299–303
Eckernâs S-A, Aquilonius SM, Hartvig P, Hagglund J, Lundqvist H, Nagren K, Långström B (1987) Positron emission tomography (PET) in the primate brain: evaluation of a kinetic model using11C-N-methyl-spiperone. Acta Neurol Scand 75:168–178
Farde L, Halldin C, Stone-Elander S, Sedvall G (1987) PET analysis of human dopamine receptor subtypes using11C-SCH23390 and11C-raclopride. Psychopharmacology 92:278–284
Fibiger HC, Phillips AG (1981) Increased intracranial self-stimulation in rats after long-term administration of desipramine. Science 214:683–685
Frost JJ, Smith AC, Kuhar MJ, Dannals RF, Wagner HN Jr (1987) In vivo binding of3H-N-methylspiperone to dopamine and serotonin receptors. Life Sci 40:987–995
Gershon ES, Berrettini W, Nurnberger J Jr, Goldin LR (1987) Genetics of affective illness. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 481–491
Hall H, Farde L, Sedvall G (1988) Human dopamine receptor subtypes-in vitro binding analysis using3H-SCH23390 and3H-raclopride. J Neural Transm 73:7–21
Klimek V, Nielsen M (1987) Chronic between with antidepressants decreases the number of [3H]SCH23390 binding sites in the rat striatum and limbic system. Eur J Pharmacol 139:163–169
Koyama T (1987) The effect of lithium treatment on activity of central dopaminergic neurons. Hokkaido-Igaku-Zasshi 62:402–416
Lundberg T, Lindstöm LH, Hartvig P, Eckernâs SA, Ekblom B, Lundqvist H, Fasth KJ, Gullberg P, Långström B (1989) Striatal and frontal cortex binding of 11-C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers. Psychopharmacology 99:8–12
Maj J, Rogz Z, Skuza G, Sowinska H (1984) Repeated between with antidepressant drugs increases the behavioural response to apomorphine. J Neural Transm 60:273–282
Maj J, Wędzony K, Klimek V (1987) Desipramine given repeatedly enhances behavioural effect of dopamine andd-amphetamine injected into the nucleus accumbens. Eur J Pharmacol 140:179–185
Matui T, Hirano A (1977) An atlas of the human brain for computerized tomography. Igaku Shoin, Tokyo
Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch M (1984) A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217–227
Nowak G, Zak J (1989) Repeated electroconvulsive shock (ECS) enhances striatal D-1 dopamine receptor turnover in rat. Eur J Pharmacol 167:307–308
Serra G, Collu M, D'Aquila PS, De Montis GM, Gessa GL (1990) Possible role of dopamine D1 receptor in the behavioural supersensitivity to dopamine agonists induced by chronic treatment with antidepressants. Brain Res 527:234–243
Silverstone T (1985) Dopamine in manic depressive illness: a pharmacological synthesis. J Affective Disord 8:225–231
Spyraki C, Fibiger HC (1981) Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol 74:195–206
Suhara T, Inoue O, Kobayasi K (1990) Effect of desipramine on dopamine receptor binding in vivo. Life Sci 47:2119–2126
Suhara T, Fukuda H, Inoue O, Itoh T, Suzuki K, Yamasaki T, Tateno Y (1991) Age-related changes in human D1 dopamine receptors measured by positron emission tomography. Psychopharmacology 103:41–45
Takami K, Ueda K, Okajima K, Tanaka E, Nohara N, Tomitani T, Murayama H, Shishido F, Ishimatu K, Ohgushi S, Inoue Y, Takakusa Y, Hayashi T, Nakase S (1983) Performance study of whole-body, multislice positron computed tomograph-positrosica II. IEEE Trans Nucl Sci NS-30:734–738
Tassin JP, Studler JM, Herve D, Blanc G, Glowinski J (1986) Contribution of noradrenergic neurons to the regulation of dopaminergic (D1) receptor denervation supersensitivity in rat prefrontal cortex. J Neurochem 46:243–248
Undie AS, Friedman E (1990) Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain. J Pharmacol Exp Ther 253:987–992
Wachtel H (1989) Dysbalance of neural second messenger function in the aetiology of affective disorders: a pathophysiological concept hypothesising defects beyond first messenger receptors. J Neural Transm 75:21–29
Whitaker-Azmitia PM, Molino LJ, Caruso J, Shemer AV (1990) Serotonergic agents restore appropriate decision-making in neonatal rats displaying dopamine D1 receptor-mediated vacillatory behavior. Eur J Pharmacol 180:305–309
Willner P (1983) Dopamine and depression: a review of recent evidence. Brain Res Rev 6:211–246
Wong DF, Wagner HN Jr, Pearlson G, Dannals RF, Links JM, Ravert HT, Wilson AA, Suneja S, Bjorvvinssen E, Kuhar MJ, Tune L (1985) Dopamine receptor binding of C-11-3-N-methylspiperone in the caudate in schizophrenia and bipolar disorder: a preliminary report. Psychopharmacol Bull 21:595–598
Wong DF, Pearlson G, Ross C, Tune L, Villemagne V, Dannals RF, Links J, Ravert H, Wilson A, Kuhar M, Wagner HN Jr, Gjedde A (1987) In vivo measurement of D2 dopamine receptor abnormalities in drug naive and drug free manic-depressive patients. Soc Neurosci Abstr 13:261
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Suhara, T., Nakayama, K., Inoue, O. et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology 106, 14–18 (1992). https://doi.org/10.1007/BF02253582
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02253582